Drugs / SI-B003
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04606472 | Nov 2020 → Dec 2025 overdue | cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05949606 | Oct 2023 → Dec 2026 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05668858 | Feb 2023 → Dec 2026 expected | head and neck squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT06668961 | Nov 2024 → Nov 2026 expected | head and neck squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05956587 | Jan 2024 → Dec 2026 expected | nasopharyngeal carcinoma, non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06042894 | Dec 2023 → Dec 2026 expected | breast cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05965856 | Dec 2023 → Dec 2026 expected | urothelial carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06008054 | Nov 2023 → Dec 2026 expected | colorectal cancer, esophageal cancer, gastric cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05924841 | Nov 2023 → Dec 2026 expected | small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05990803 | Nov 2023 → Dec 2026 expected | cervical cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06006169 | Oct 2023 → Dec 2026 expected | head and neck squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SI-B003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05990803 ↗ |
| Modality | Monoclonal antibody | “SI-B003, a PD-1/CTLA-4 Bispecific Antibody” NCT04606472 ↗ |
| Route | Intravenous | “Administration by intravenous infusion.” NCT04606472 ↗ |